BostonGene Demonstrates Disease Modeling Platform at JSMO 2026, Advancing AI-Driven Drug Development and Precision Oncology

Thursday, March 26, 2026 · media contact:

AI Briefing

BostonGene showcases AI-driven disease modeling platform at JSMO 2026, advancing drug development and precision oncology.
The 23rd Annual Meeting of the Japanese Society of Medical Oncology brings together over 7,000 global experts to discuss cancer research and clinical practice.
BostonGene's platform aims to bridge the gap between evidence and reality in cancer research.